Alvotech
A global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. It specializes in making biosimilars to improve lives by expanding access to affordable biologic medicines. The company is listed on NASDAQ under the ticker ALVO.
History
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. It specializes in making biosimilars to improve lives by expanding access to affordable biologic medicines. The company is listed on NASDAQ under the ticker ALVO.
Controversies
2021
AbbVie files second suit against Alvotech
AbbVie brought a second action against Alvotech hf. in the Northern District of Illinois, alleging patent infringement in connection with Alvotech’s proposed HUMIRA biosimilar.
2021
Alvotech files suit against AbbVie over Humira patents
Alvotech USA and Alvotech hf filed a declaratory-judgment complaint against AbbVie in the Eastern District of Virginia, alleging that patents in AbbVie’s Humira portfolio were invalid or unenforceable and seeking declaratory judgments of non-infringement and invalidity.
Recent events
FDA approves Alvotech manufacturing process for SIMLANDI[8]
Reported:
The U.S. FDA approved Alvotech's Process 2.0 for manufacturing SIMLANDI (adalimumab-ryvk) drug substance at its Reykjavik facility. The process more than doubles output per batch without changing the upstream manufacturing scale.
AbbVie files second suit against Alvotech[6]
AbbVie brought a second action against Alvotech hf. in the Northern District of Illinois, alleging patent infringement in connection with Alvotech’s proposed HUMIRA biosimilar.
Alvotech files suit against AbbVie over Humira patents[7]
Alvotech USA and Alvotech hf filed a declaratory-judgment complaint against AbbVie in the Eastern District of Virginia, alleging that patents in AbbVie’s Humira portfolio were invalid or unenforceable and seeking declaratory judgments of non-infringement and invalidity.
Cipla Gulf expands biosimilar partnership with Alvotech[9]
Reported:
Cipla announced that its subsidiary Cipla Gulf was expanding its partnership with Alvotech to commercialize and distribute four biosimilar medicines in Australia and New Zealand. Alvotech develops and manufactures the products, and Cipla Gulf handles commercialization and distribution.
- Unconfirmed
JAMP Pharma and Alvotech sign Canadian biosimilar commercialization agreement[10]
Reported:
JAMP Pharma Group signed an exclusive agreement with Alvotech for the Canadian commercial rights to five biosimilars.
Sources10 sources
- 1Alvotech - Better Access Better Livesalvotech.com
- 2Creating a healthier world through affordable biologicsalvotech.com
- 3Our approach to Biosimilarsalvotech.com
- 4Alvotech to present at upcoming investor conferences in Septemberalvotech.com
- 5Alvotechwikidata.org
- 6AbbVie files second suit against Alvotechjdsupra.com
- 7Alvotech files suit against AbbVie over Humira patentsjdsupra.com
- 8FDA批准Alvotech用于SIMLANDI的制造工艺finanznachrichten.de
- 9Cipla Gulf与Alvotech扩大生物类似药合作business-standard.com
- 10JAMP Pharma与Alvotech签署加拿大生物类似药商业化协议newswire.ca
Cite this profile: Cite the canonical profile. /brand-wiki/alvotech · Editorial policy · How profiles are compiled